| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Wei Liu, Jingqi Zhou, Minjuan Cao, Fangming Zhang, Xiaoming Su. A pharmacokinetic analysis of amisulpride in adult Chinese patients with schizophrenia: Impact of creatinine clearance. International journal of clinical pharmacology and therapeutics. 2023-03-05. PMID:36871243. |
to develop a stable population pharmacokinetic (ppk) model of amisulpride and to investigate the effects of covariates on the pharmacokinetic parameters in adult chinese patients with schizophrenia. |
2023-03-05 |
2023-08-14 |
Not clear |
| Itay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, Michael Lamson, Eran Harary, Ofer Spiegelstein, Attila Kalmanczhelyi, Ryan Tiver, Pippa Loupe, Micha Levi, Anna Elgar. Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone. Clinical pharmacology in drug development. 2022-03-04. PMID:35245409. |
the ppk model was created by applying pharmacokinetic data from a phase 1 study of 97 patients with a diagnosis of schizophrenia or schizoaffective disorder who received either single or repeated doses of tv-46000. |
2022-03-04 |
2023-08-13 |
Not clear |
| Shanqing Huang, Lu Li, Zhanzhang Wang, Tao Xiao, Xiaolin Li, Shujing Liu, Ming Zhang, Haoyang Lu, Yuguan Wen, Dewei Shan. Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level. Drug design, development and therapy. vol 15. 2021-09-23. PMID:34548782. |
to explain the high inter-individual variability (iiv) and the frequency of exceeding the therapeutic reference range and the laboratory alert level of amisulpride, a population pharmacokinetic (ppk) model in chinese patients with schizophrenia was built based on therapeutic drug monitoring (tdm) data to guide individualized therapy. |
2021-09-23 |
2023-08-13 |
Not clear |
| Ismael Olmos, Manuel Ibarra, Marta Vázquez, Cecilia Maldonado, Pietro Fagiolino, Gustavo Giachett. Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia. BioMed research international. vol 2019. 2019-07-22. PMID:30956977. |
so the goal of this study was to evaluate the magnitude and variability of concentration exposure to czp and its active metabolite nczp on pharmacokinetic parameters in uruguayan patients with schizophrenia with a focus on covariates such as cigarette smoking, age, sex, caffeine consumption, brands available of czp, and comedication using population pk (ppk) modeling methodologies. |
2019-07-22 |
2023-08-13 |
Not clear |
| Li-jun Li, De-wei Shang, Wen-biao Li, Wei Guo, Xi-pei Wang, Yu-peng Ren, An-ning Li, Pei-xin Fu, Shuang-min Ji, Wei Lu, Chuan-yue Wan. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia. Acta pharmacologica Sinica. vol 33. issue 11. 2013-11-07. PMID:22820910. |
to develop a combined population pharmacokinetic model (ppk) to assess the magnitude and variability of exposure to both clozapine and its primary metabolite norclozapine in chinese patients with refractory schizophrenia via sparse sampling with a focus on the effects of covariates on the pharmacokinetic parameters. |
2013-11-07 |
2023-08-12 |
Not clear |
| Yuyan Jin, Bruce G Pollock, Kim Coley, Del Miller, Stephen R Marder, Jeff Florian, Lon Schneider, Jeffrey Lieberman, Margaret Kirshner, Robert R Bie. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. Journal of clinical pharmacology. vol 50. issue 1. 2010-03-22. PMID:19843655. |
the goal of the study was to characterize population pharmacokinetics (ppk) for perphenazine in patients with schizophrenia from the clinical antipsychotic trials of intervention effectiveness (catie). |
2010-03-22 |
2023-08-12 |
Not clear |